202 related articles for article (PubMed ID: 36826464)
21. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
22. A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.
Rosas E; Roberts JT; O'Neill KI; Christenson JL; Williams MM; Hanamura T; Spoelstra NS; Vahrenkamp JM; Gertz J; Richer JK
Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33294922
[TBL] [Abstract][Full Text] [Related]
23. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
24. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
25. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
[TBL] [Abstract][Full Text] [Related]
26. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
[TBL] [Abstract][Full Text] [Related]
27. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
28. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
29. CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.
Yuan X; Hao X; Chan HL; Zhao N; Pedroza DA; Liu F; Le K; Smith AJ; Calderon SJ; Lieu N; Soth MJ; Jones P; Zhang XH; Rosen JM
bioRxiv; 2024 Apr; ():. PubMed ID: 38712292
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
31. [The roles of c-Jun and CBP in the inhibitory effect of quercetin on prostate cancer cells].
Yuan HQ; Guo HF; He ML; Kong F; Hu XY; Jiang AL; Xu X; Zhang JY; Charles YF
Yao Xue Xue Bao; 2006 Sep; 41(9):819-24. PubMed ID: 17111826
[TBL] [Abstract][Full Text] [Related]
32. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
33. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
[TBL] [Abstract][Full Text] [Related]
34. HTLV-1 Tax oncoprotein inhibits the estrogen-induced-ER α-Mediated BRCA1 expression by interaction with CBP/p300 cofactors.
Shukrun M; Jabareen A; Abou-Kandil A; Chamias R; Aboud M; Huleihel M
PLoS One; 2014; 9(2):e89390. PubMed ID: 24586743
[TBL] [Abstract][Full Text] [Related]
35. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription.
Cougot D; Wu Y; Cairo S; Caramel J; Renard CA; Lévy L; Buendia MA; Neuveut C
J Biol Chem; 2007 Feb; 282(7):4277-4287. PubMed ID: 17158882
[TBL] [Abstract][Full Text] [Related]
36. Endocrine disrupting chemicals may deregulate DNA repair through estrogen receptor mediated seizing of CBP/p300 acetylase.
Lakshmanan MD; Shaheer K
J Endocrinol Invest; 2020 Sep; 43(9):1189-1196. PubMed ID: 32253726
[TBL] [Abstract][Full Text] [Related]
37. Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.
Culig Z
J Cell Physiol; 2016 Feb; 231(2):270-4. PubMed ID: 26201947
[TBL] [Abstract][Full Text] [Related]
38. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
Du C; Huang D; Peng Y; Yao Y; Zhao Y; Yang Y; Wang H; Cao L; Zhu WG; Gu J
Cancer Lett; 2017 Aug; 400():183-193. PubMed ID: 28465257
[TBL] [Abstract][Full Text] [Related]
39. CBP/p300 Bromodomain Inhibitor-I-CBP112 Declines Transcription of the Key ABC Transporters and Sensitizes Cancer Cells to Chemotherapy Drugs.
Strachowska M; Gronkowska K; Michlewska S; Robaszkiewicz A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572840
[TBL] [Abstract][Full Text] [Related]
40. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
